ArticleNature communications2026
Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
PTEN and p53 are two pivotal tumor suppressors that synergistically restrain tumor progression but are frequently inactivated in cancer. Restoring their functions is a promising therapeutic strategy but remains limited by unsustainable protein production and off-target effects. Here, we report a biohybrid platform integrating engineered attenuated Salmonella typhimurium VNP20009 with nanotechnology to enable durable restoration of PTEN and p53 functions in tumors. The bacteria are engineered with a quorum-sensing-regulated lysis circuit coupled to PTEN expression, enabling controlled proliferation and sustained PTEN production and release. Their intrinsic tumor tropism and long-term intracellular parasitism allow them to function as exogenous organelle mimics, providing continuous PTEN supplementation. Surface-conjugated nanoparticles further deliver the MDM2 inhibitor to stabilize p53 and synergistically restore the PTEN-p53 network. This platform achieves 94.9% tumor inhibition in murine melanoma and confers durable survival in all treated mice when combined with anti-PD-1 therapy, highlighting its strong therapeutic potential for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.